Appeal No. 95-1390
Application 07/752,639
11. A method of differentiating in a test sample antibodies arising from HTLV-I
infection and antibodies arising from HTLV-II infection comprising analyzing the test
sample in at least four immunoassays that each employ
(I) at least one synthetic peptide from each of groups a) to d):
a) a synthetic peptide comprising 17 to 68 amino acids and at least one
antigenic structure, said peptide derived from the HTLV-I gag gene;
b) a synthetic peptide comprising at least 17 amino acids and at least one
antigenic structure, said peptide derived from the HTLV-II gag gene;
c) a synthetic peptide comprising at least 17 amino acids and at least one
antigenic structure, said peptide derived from the HTLV-I env gene;
d) a synthetic peptide comprising at least 17 amino acids and at least one
antigenic structure, said peptide derived from the HTLV-II env gene; and
(ii) at least one pair of synthetic peptides derived from HTLV-I and HTLV-II gene
sequences selected from each of the groups a) plus b), and c) plus d);
wherein each of said immunoassays employs a different synthetic peptide selected
from groups a) to d).
13. An immunoassay kit for differentiating in a test sample antibodies arising from
HTLV-I infection and antibodies arising from HTLV-II infection comprising one or more
containers holding synthetic peptides for analyzing a test sample in at least four
immunoassays, said synthetic peptides comprising at least one peptide selected from
each of groups a) to d):
a) a synthetic peptide comprising at least 17 amino acids and at least one
antigenic structure, said peptide derived from the HTLV-I gag gene;
b) a synthetic peptide comprising at least 17 amino acids and at least one
antigenic structure, said peptide derived from the HTLV-II gag gene;
c) a synthetic peptide comprising at least 17 amino acids and at least one
antigenic structure, said peptide derived from the HTLV-I env gene; and
4
Page: Previous 1 2 3 4 5 6 7 8 9 Next
Last modified: November 3, 2007